Identifying genetic and DNA markers for lung cancer risk.
Identification of Genes and DNA Methylation Markers for Lung Cancer Risk by Integrating Multi-omics Data
['FUNDING_R01'] · VANDERBILT UNIVERSITY MEDICAL CENTER · NIH-11011316
This study is looking at how our genes and their changes can affect the risk of lung cancer, so that patients can learn more about their personal risk and find better ways to prevent and treat the disease.
Quick facts
| Phase | ['FUNDING_R01'] |
|---|---|
| Study type | Nih_funding |
| Sex | All |
| Sponsor | VANDERBILT UNIVERSITY MEDICAL CENTER (nih funded) |
| Locations | 1 site (NASHVILLE, UNITED STATES) |
| Trial ID | NIH-11011316 on ClinicalTrials.gov |
What this research studies
This research investigates the genetic and epigenetic factors that contribute to lung cancer risk by integrating various types of biological data. It utilizes advanced techniques like transcriptome-wide association studies (TWAS) and methylation-wide association studies (MeWAS) to uncover new genes and DNA methylation markers associated with lung cancer. By analyzing genetic variants and their effects on gene expression and DNA methylation, the study aims to identify potential targets for prevention and treatment. Patients may benefit from insights into their genetic risk factors and personalized approaches to lung cancer management.
Who could benefit from this research
Good fit: Ideal candidates for this research include individuals with a family history of lung cancer or those at high risk due to environmental factors.
Not a fit: Patients with no genetic predisposition to lung cancer or those who do not meet the study's risk criteria may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to improved risk assessment and targeted prevention strategies for lung cancer patients.
How similar studies have performed: Previous studies using similar approaches have successfully identified novel genetic and methylation markers in various cancers, indicating the potential effectiveness of this methodology.
Where this research is happening
NASHVILLE, UNITED STATES
- VANDERBILT UNIVERSITY MEDICAL CENTER — NASHVILLE, UNITED STATES (ACTIVE)
Researchers
- Principal investigator: CAI, QIUYIN — VANDERBILT UNIVERSITY MEDICAL CENTER
- Study coordinator: CAI, QIUYIN
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.
Conditions: Breast Cancer, Cancer Biology